Screening for metastasis in primary breast cancer patients having four or more axillary lymph node involvement: is it really necessary?

Basit Öğe Kaydı
dc.contributor.authorUslu, R.
dc.contributor.authorKapkac, M.
dc.contributor.authorKaraca, B.
dc.contributor.authorCamyar, H.
dc.contributor.authorDurusoy, R.
dc.contributor.authorOzdemir, N.
dc.contributor.authorAras, A. B.
dc.contributor.authorOktay, A.
dc.contributor.authorOzkilic, H.
dc.contributor.authorYilmaz, R.
dc.date.accessioned2019-10-27T21:16:36Z
dc.date.available2019-10-27T21:16:36Z
dc.date.issued2010
dc.departmentEge Üniversitesien_US
dc.description.abstractPurpose: To evaluate the necessity and direct cost effectiveness of screening and staging procedures in breast cancer patients having >= 4 positive axillary lymph nodes and to identity further possible biopathological risk factors associated with increased risk of metastasis. Methods: We reviewed the demographic and clinicopathological data from the medical records of 1897 newly diagnosed breast cancer patients. Patients having >= 4 positive axillary lymph nodes after primary surgery for breast cancer and who had staging examinations for metastasis were eligible. The impact of staging procedures (thoracoabdominal CT, bone scan etc.) for detecting metastasis, decision of adjuvant treatment and direct costs were analyzed in 329 patients with operable breast cancer Results: Thirty-five (10.6%) patients were found with metastasis at diagnosis. Seven (20.0%) among them had multiple metastases. Eighteen (51.4%) had lung, 17(48.6%) bone, and 7 (20.0%) liver metastasis. Twenty-one (60.0%) patients needed further radiological investigation for metastasis confirmation. Treatment decision was changed in 27 (77.1%) patients. No statistically significant risk factor was identified among the metastatic patients by means of conventional demographic and biopathological parameters. The cost of screening was lower when compared to the cost of treatment without any screening procedure. Conclusion: Since the conventional clinicopathological data seems not sufficient to define the risk of developing metastasis in breast cancer patients with >= 4 axillary lymph node involvement, all of them should undergo full staging examinations until new parameters based on genomic level are defined. Staging procedures need modification for high risk breast cancer patients.en_US
dc.identifier.endpage567en_US
dc.identifier.issn1107-0625
dc.identifier.issn2241-6293
dc.identifier.issue3en_US
dc.identifier.pmid20941828en_US
dc.identifier.startpage561en_US
dc.identifier.urihttps://hdl.handle.net/11454/43693
dc.identifier.volume15en_US
dc.identifier.wosWOS:000282621800022en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherImprimatur Publicationsen_US
dc.relation.ispartofJournal of Buonen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectaxillary lymph node involvementen_US
dc.subjectbiopathological parametersen_US
dc.subjectbreast canceren_US
dc.subjectcostsen_US
dc.subjectmetastasisen_US
dc.subjectstagingen_US
dc.titleScreening for metastasis in primary breast cancer patients having four or more axillary lymph node involvement: is it really necessary?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu